U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

TOFOGLIFLOZIN ANHYDROUS

MORE DETAILS

  554245W62T

Status:
Possibly Marketed Outside US
Source:
DEBERZA by Chugai Pharmaceutical
Source URL:
https://www.ncbi.nlm.nih.gov/pubmed/24848755
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Sodium/glucose cotransporter 2
25
Conditions:
Type 2 diabetes mellitus
262
Tofogliflozin is a SGLT2 selective inhibitor which was developed by Chugai Pharmaceutical for the treatment of Type 2 Diabetes Mellitus. The drug was approved in Japan in 2013 and it is being marketed under the names Apleway and Debereza.

TOFOGLIFLOZIN

MORE DETAILS

  P8DD8KX4O4

Status:
Possibly Marketed Outside US
Source:
DEBERZA by Chugai Pharmaceutical
Source URL:
https://www.ncbi.nlm.nih.gov/pubmed/24848755
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Sodium/glucose cotransporter 2
25
Conditions:
Type 2 diabetes mellitus
262
Tofogliflozin is a SGLT2 selective inhibitor which was developed by Chugai Pharmaceutical for the treatment of Type 2 Diabetes Mellitus. The drug was approved in Japan in 2013 and it is being marketed under the names Apleway and Debereza.
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966